Blog: Research

3D printing brain scans helps doctors with a tricky diagnosis

5 October 2017

Source Tech Crunch:

When there’s a problem in the brain, it pays to be precise — every millimeter counts with something like a tumor or blocked artery.

Long-term Lemtrada Treatment Benefits Demonstrated in Extension Study

4 October 2017

Source Multiple Sclerosis News Today:

A five-year study demonstrated that Sanofi-Genzyme’s Lemtrada (alemtuzumab) provides long-term benefits for relapsing-remitting multiple sclerosis patients, reducing relapse rates and preventing the progression of the disease.

Importantly, most patients required only the standard two-phase treatment course. Few needed additional courses because of relapse or new brain lesions....

Disarm Therapeutics to Begin Developing Therapy that Prevents Axonal Degeneration

22 September 2017

Source Multiple Sclerosis News Today:

Disarm Therapeutics has completed the first round of financing to develop a compound that prevents axonal degeneration in patients with multiple sclerosis (MS) and other neurodegenerative conditions.

New study to look at impact of early treatment with aggressive DMTs

22 September 2017

Source MS Society:

A new study will investigate whether early treatment with aggressive disease modifying therapies (DMTs) could benefit people with MS.

Gut Microbes May Influence Multiple Sclerosis Progression

12 September 2017

Source University of California San Francisco:

Researchers at UC San Francisco have identified specific gut microbes associated with multiple sclerosis (MS) in human patients, and show that these microbes take part in regulating immune responses in mouse models of the disease.

European Commission reverses decision on drug, following QMUL research

12 September 2017

Source Queen Mary University of London:

A drug for multiple sclerosis (MS) has been granted a license by the European Commission, following evidence from Queen Mary University of London (QMUL) that it improves patients’ quality of life and is safer than previously thought.

MS Society Research Talk has been rescheduled:

12 September 2017

Research Talk

Date: Monday 13th November 2017, Time: 10:30 - 13:30 Venue: The Salvation Army Hall Chalfont Close, Lower Earley, RG6 5HZ

Drugs in development

5 September 2017

Source MS Trust:

The development of new drugs is a long and difficult process. Fewer than one or two compounds in 10,000 tested actually make it through to being licensed treatments with many being rejected on safety, efficacy or quality grounds.

Cladribine: NICE looking at new treatment for MS

5 September 2017

Source MS Society:

The European Medicines Agency (EMA) has licensed cladribine (also known as Mavenclad) to treat people with highly active relapsing MS.

The National Institute for Health and Care Excellence (NICE) will now decide whether to make it available on the NHS in England and Wales. The Scottish Medicines Consortium (SMC) will decide for Scotland.

How does it work? Cladribine is currently used as an anti-cancer drug. In MS, the body’s own immune cells...

Cladribine (Mavenclad) gets European licence for highly active relapsing MS

30 August 2017

Source MS Trust:

The European Commission (EC) has granted marketing authorization for cladribine (Mavenclad)for the treatment of adults with highly active relapsing multiple sclerosis. This follows a recommendation from the European Medicines Agency in June that a licence should be granted.

Pages

Category

Archive